Novel mitochondrial complex I-inhibiting peptides restrain NADH dehydrogenase activity

Sci Rep. 2019 Sep 23;9(1):13694. doi: 10.1038/s41598-019-50114-2.

Abstract

The emergence of drug-resistant fungal pathogens is becoming increasingly serious due to overuse of antifungals. Antimicrobial peptides have potent activity against a broad spectrum of pathogens, including fungi, and are considered a potential new class of antifungals. In this study, we examined the activities of the newly designed peptides P-113Du and P-113Tri, together with their parental peptide P-113, against the human fungal pathogen Candida albicans. The results showed that these peptides inhibit mitochondrial complex I, specifically NADH dehydrogenase, of the electron transport chain. Moreover, P-113Du and P-113Tri also block alternative NADH dehydrogenases. Currently, most inhibitors of the mitochondrial complex I are small molecules or artificially-designed antibodies. Here, we demonstrated novel functions of antimicrobial peptides in inhibiting the mitochondrial complex I of C. albicans, providing insight in the development of new antifungal agents.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / pharmacology*
  • Candida albicans / drug effects*
  • Candida albicans / metabolism
  • Electron Transport Complex I / antagonists & inhibitors*
  • Histatins / pharmacology*
  • Microbial Sensitivity Tests
  • Mitochondria / drug effects
  • Mitochondria / metabolism
  • NADH Dehydrogenase / metabolism*
  • Reactive Oxygen Species / metabolism

Substances

  • Antifungal Agents
  • Histatins
  • P-113D
  • P-113Tri
  • Reactive Oxygen Species
  • NADH Dehydrogenase
  • Electron Transport Complex I